Related Topics News -

     
 Detail   |   Print    Next page > 
     
聯邦制藥度普利尤單抗注射液獲臨床試驗默示許可
2026-04-22T  
國家醫保局:將著優化集採規則及強化結果落地實施等
2026-04-15T  
《大行》瑞銀降聯邦制藥目標價至17.6元 去年業績符預期
2026-03-26T  
聯邦制藥:UBT251注射液II期臨床研究達預期目標 將盡快啟動III期研究
2026-03-25T  
《業績》聯邦制藥全年純利20.86億人民幣跌21.6% 末期息派26分
2026-03-25T  
《盈警》聯邦制藥預告去年溢利降24.8%至20億人民幣
2026-03-12T  
聯邦制藥德谷胰島素注射液獲批
2026-03-09T  
《大行》瑞銀料醫療健康板塊收入今年續增長10% 改列三生製藥為首選
2026-02-27T  
《大行》瑞銀對醫療健康股投資評級及目標價(表)
2026-02-27T  
《大行》華泰證券指聯邦製藥UBT251 II期數據驚艷催化全球潛力 維持「買入」評級
2026-02-27T  
  Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.